Imago has translated state-of-the-art science into novel medicines for the treatment of diseases that pose great challenges to patients, their physicians and their families. Our strength derives from our focus on a handful of devastating but related diseases, the skills and experience of our team, and the commitment of our investors.
Our Inspiration – The Patients

Imago BioSciences has developed inhibitors of the enzyme lysine-specific demethylase 1 (LSD1). LSD1 Inhibitor – The Patients

Our Inspiration
Pipeline

Pipeline

Pipeline
Programs

Programs

Programs
Our Inspiration – The Patients

Our Inspiration – The Patients

Our Inspiration
Pipeline

Pipeline

Pipeline
Programs

Programs

Programs

Imago’s Name

Our name, Imago, (pron. i-mắ-go), invokes the final and fully developed stage of an insect after its metamorphosis. In this process of growth and development, the imago refers to the fully formed adult, one that has completed its transformation and, for a butterfly, has taken flight. In our view, the full maturation of a scientific idea or observation in medical research is when new treatments prove their worth in clinical studies. To patients, anything less is to miss the mark.

Learn
About us

Imago is developing pioneering medicines for the treatment of myeloproliferative diseases.

Meet Our Team

Meet
Our Investors

Imago BioSciences is a clinical-stage, private therapeutics company focused on malignant and life-threatening diseases of the bone marrow.

Investors

Our News